Bibliografia
Ruggeri M, Bottan F, Chiarugi P et al. (2001) Linee guida per la diagnostica ed il monitoraggio delle gammapatie monoclonali. Riv Med Lab-JLM 2(S1):68–71
Caldini A, Graziani MS, Basile U et al. (2014) Il contributo della diagnostica proteica nella gestione delle gammapatie monoclonali. Biochimica Clinica 38:47–53
Dimopoulos M, Kyle R, Fermand JP et al. (2011) Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3. Blood 117:4701–4705
Kyle RA, Durie BG, Rajkumar SV et al. (2010) Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management. Leukemia 24:1121–1127
Berenson JR, Anderson KC, Audell RA et al. (2010) Monoclonal gammopathy of undetermined significance: a consensus statement. Br J Haematol 150:28–38
Bird J, Behrens J, Westin J et al. (2009) UK Myeloma Forum (UKMF) and Nordic Myeloma Study Group (NMSG): guidelines for the investigation of newly detected M-proteins and the management of monoclonal gammopathy of undetermined significance (MGUS). Br J Haematol 147:22–42
Durie BG, Harousseau JL, Miguel JS et al. (2006) International uniform response criteria for multiple myeloma. Leukemia 20:1467–1473
Wadhera RK, Kyle RA, Larson DR et al. (2011) Incidence, clinical course, and prognosis of secondary monoclonal gammopathy of undetermined significance in patients with multiple myeloma. Blood 118:2985–2987
Kyle RA, Therneau TM, Rajkumar SV et al. (2002) A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N Engl J Med 346:564–569
Rajkumar SV, Kyle RA, Therneau TM et al. (2005) Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance. Blood 106:812–817
Turesson I, Kovalchik SA, Pfeiffer RM et al. (2014) Monoclonal gammopathy of undetermined significance and risk of lymphoid and myeloid malignancies: 728 cases followed up to 30 years in Sweden. Blood 123:338–345
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflitti di interesse
Nessuno.
Studi condotti su esseri umani e animal
Per questo tipo di studio non è richiesto l’inserimento di alcuna dichiarazione relativa agli studi effettuati su esseri umani e animali.
Consenso informato
Il consenso informato è stato ottenuto da tutti i pazienti inclusi nello studio.
Rights and permissions
About this article
Cite this article
Simula, M.P., Fabris, A., Festini, G. et al. Cambiamento dell’isotipo di componenti monoclonali note: due casi clinici. Riv Ital Med Lab 12, 252–255 (2016). https://doi.org/10.1007/s13631-016-0133-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13631-016-0133-7